Alpha-Blocker & Vasoactive Peptide Combinations
Phentolamine mesylate is a non-selective alpha-adrenergic antagonist used in combination with vasoactive peptides (VIP, prostaglandin E1) for intracavernosal injection therapy in erectile dysfunction. The VIP/phentolamine combination (Invicorp) and papaverine/phentolamine/PGE1 triple therapy (Trimix) are established second-line treatments for ED refractory to oral PDE5 inhibitors.
Overview
Phentolamine has been used in urology since the early 1980s when Brindley (1983) demonstrated that intracavernosal injection of vasoactive agents could produce erections sufficient for intercourse. The physiological rationale is straightforward: penile detumescence is maintained by tonic sympathetic alpha-adrenergic signaling that keeps corporal smooth muscle contracted. By blocking alpha-1 and alpha-2 adrenoceptors, phentolamine removes this sympathetic tone, permitting vasodilation and sinusoidal filling.
However, alpha-blockade alone is typically insufficient for full erection because the active relaxation component — mediated by NO, VIP, and prostaglandins — is also required. This is why phentolamine is almost exclusively used in combination:
- Invicorp: VIP 25 mcg + phentolamine 1–2 mg — combines NANC-mediated relaxation (VIP/cAMP) with alpha-blockade
- Trimix: Papaverine 30 mg + phentolamine 0.5–1 mg + PGE1 (alprostadil) 10–20 mcg — combines non-specific phosphodiesterase inhibition, alpha-blockade, and prostaglandin receptor-mediated relaxation
- Bimix: Papaverine + phentolamine (without PGE1) — simpler formulation with lower pain incidence
Gerstenberg et al. (1992) established the VIP/phentolamine combination as a viable clinical therapy, demonstrating that the synergistic interaction produced rigid erections in the majority of ED patients while minimizing the risk of priapism compared to prostaglandin-based monotherapy.
Mechanism of Action
Phentolamine enhances erectile function through complementary anti-adrenergic mechanisms:
- Alpha-1 adrenoceptor blockade: Blocks post-synaptic alpha-1 receptors on corporal smooth muscle, preventing norepinephrine-mediated contraction via the IP3/DAG/calcium pathway. This is the primary mechanism of detumescence inhibition, as alpha-1 receptors mediate the tonic sympathetic contraction that keeps the penis flaccid (Andersson & Wagner, 1995)
- Alpha-2 adrenoceptor blockade: Blocks pre-synaptic alpha-2 autoreceptors on sympathetic nerve terminals, paradoxically increasing norepinephrine release but preventing its post-synaptic action. Also blocks alpha-2 receptors on endothelial cells, potentially enhancing NO release
- Synergy with VIP (Invicorp): VIP provides active cAMP-mediated smooth muscle relaxation while phentolamine removes opposing sympathetic contractile tone. The combination addresses both the "accelerator" (active relaxation) and "brake" (sympathetic contraction) of erectile physiology (Dinsmore et al., 1999)
- Synergy with papaverine and PGE1 (Trimix): Papaverine inhibits phosphodiesterases non-selectively (raising both cAMP and cGMP), phentolamine blocks alpha-adrenergic contraction, and PGE1 activates EP receptor-mediated relaxation via cAMP. The three mechanisms converge on smooth muscle relaxation through parallel signaling pathways
Reconstitution Calculator
Research
VIP/Phentolamine Combination (Invicorp)
Dinsmore et al. (1999) reported results from a multicenter Phase III trial of Invicorp in 636 men with ED of various etiologies. The combination of VIP 25 mcg + phentolamine 1 mg produced erections sufficient for intercourse in 67% of patients versus 19% for placebo. The response was consistent across vasculogenic, neurogenic, psychogenic, and mixed ED. Key advantages over alprostadil included significantly lower incidence of penile pain (3% vs 30%) and priapism (<1% vs 1–3%).
Oral Phentolamine (Vasomax)
Goldstein et al. (2001) conducted Phase III trials of oral phentolamine mesylate (Vasomax, 40–80 mg) for mild to moderate ED. Oral phentolamine significantly improved erectile function compared to placebo, with 55% of patients achieving erections sufficient for intercourse at the 80 mg dose. However, the FDA did not approve Vasomax due to concerns about genotoxicity in preclinical assays (Ames test), and the drug was withdrawn from the regulatory pipeline. It was briefly approved in Brazil and Mexico before being discontinued.
Comparison with PDE5 Inhibitors
Intracavernosal phentolamine combinations occupy the second-line treatment position for ED, after failure of oral PDE5 inhibitors. The distinct mechanism — direct alpha-blockade and cAMP-mediated relaxation rather than cGMP potentiation — provides efficacy in patients with severe endothelial dysfunction, post-prostatectomy nerve damage, or diabetes-related neuropathy where the NO/cGMP pathway is significantly impaired. McMahon et al. (1999) found that approximately 70% of PDE5 inhibitor non-responders achieved satisfactory erections with intracavernosal combination therapy.
Triple Therapy (Trimix)
Trimix (papaverine + phentolamine + PGE1) is the most widely used compounded intracavernosal formulation in North America, despite never receiving formal FDA approval as a combination product. Bennett et al. (1991) first described the triple agent approach, demonstrating that the addition of PGE1 to the papaverine/phentolamine combination increased efficacy from 65% to 92% while permitting lower doses of each component, thereby reducing side effects. Standard Trimix formulations typically contain papaverine 30 mg/mL, phentolamine 1 mg/mL, and alprostadil 10–40 mcg/mL, with dose titration guided by individual response.
Vasoactive peptide plus alpha-blocker combination therapy for ED
This entry covers combinations of the vasoactive peptide VIP (aviptadil) with the approved alpha-adrenergic blocker phentolamine mesylate, marketed as Invicorp for intracavernosal treatment of erectile dysfunction. The rationale is complementary hemodynamics: phentolamine antagonizes alpha-adrenergic tone to increase arterial inflow, while VIP relaxes cavernosal smooth muscle and supports the veno-occlusive mechanism. Randomized and real-world data over three decades show efficacy in the majority of men, including those who fail PDE5 inhibitors or cannot tolerate alprostadil.
- Randomized auto-injector study: response rates of 66-75% vs ~10-12% placebo (p<0.001).
- 2025 real-world series: effective in 59% of alprostadil-refractory/-intolerant men.
- Consistently lower injection pain than alprostadil, a key tolerability advantage.
Safety and tolerability profile
Across studies the combination is well tolerated. The dominant adverse event is transient facial flushing (driven by VIP), while priapism is rare (~0.05% of injections in the large auto-injector series) and penile pain is uncommon relative to alprostadil. Phentolamine mesylate itself is an approved alpha-blocker with a long clinical track record, contributing to the favorable safety profile of the combination.
- Transient facial flushing is the principal side effect (~34% of injections).
- Priapism is rare (two episodes / 0.05% in the 304-patient trial).
- Low incidence of penile pain, unlike alprostadil-based intracavernosal therapy.
Safety Profile
The safety profile of phentolamine-containing intracavernosal combinations varies by formulation:
- Hypotension: Systemic alpha-blockade can cause orthostatic hypotension, particularly in patients on antihypertensive medications. Typically mild and transient with intracavernosal dosing due to limited systemic absorption
- Nasal congestion: Reported in ~5–10% of patients due to alpha-blockade of nasal vasculature
- Dizziness: Related to systemic vasodilation; more common with oral formulations
- Tachycardia: Reflex tachycardia from peripheral vasodilation; usually subclinical with intracavernosal dosing
- Priapism: Risk varies by formulation — Invicorp (VIP/phentolamine) has the lowest risk (<1%); Trimix has moderate risk (~1–3%), which increases with higher papaverine doses. All patients must be instructed in priapism emergency management (Dinsmore et al., 1999)
- Penile fibrosis: Long-term intracavernosal injection carries a cumulative risk of corporal fibrosis (Peyronie's-like plaques), estimated at 5–10% over 3–5 years, primarily attributed to the papaverine component rather than phentolamine
- Contraindications: Concurrent use of MAO inhibitors, severe cardiovascular disease, conditions predisposing to priapism, hypersensitivity to phentolamine or any combination component
Pharmacokinetic Profile
Alpha-Blocker & Vasoactive Peptide Combinations — Pharmacokinetic Curve
Intracavernosal injection (combination), oral (investigational)Quick Start
- Route
- Intracavernosal injection (combination), oral (investigational)
Molecular Structure
- Formula
- C17H19N3O·CH4O3S
- Weight
- 377.46 Da
- CAS
- 65-28-1
Research Indications
Erectile Dysfunction (intracavernosal therapy)
Vasoactive intestinal polypeptide (VIP/aviptadil) combined with the alpha-blocker phentolamine mesylate (Invicorp) is an established second-line intracavernosal injection for men who fail oral PDE5 inhibitors.
Used when alprostadil causes intolerable penile pain or fails at maximal dose; the VIP/phentolamine combination has a markedly lower incidence of injection pain.
Pharmacologic Rationale
Phentolamine (alpha-adrenergic blocker) increases cavernosal arterial inflow while VIP enhances the veno-occlusive mechanism, giving synergistic erection support.
Research Protocols
oral
Oral Phentolamine (Vasomax) [Goldstein et al. Oral phentolamine significantly improved erectile function compared to placebo, with 55% of patients achieving erections sufficient for intercourse at the 80 mg dose.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Combination | 25 mcg, 1–2 mg, 30 mg, 0.5–1 mg, 10–20 mcg | Per protocol | — |
| Intercourse in | 25 mcg, 1 mg | Per protocol | — |
| Papaverine | 30 mg, 1 mg, 10–40 mcg | Per protocol | — |
| Mild to moderate ED | 40–80 mg | Per protocol | — |
Interactions
Peptide Interactions
Intracavernosal phentolamine combinations occupy the second-line treatment position for ED, after failure of oral PDE5 inhibitors. The distinct mechanism — direct alpha-blockade and cAMP-mediated relaxation rather than cGMP potentiation — provides efficacy in patients with severe endothelial dysf...
What to Expect
What to Expect
Rapid onset expected; half-life of ~19 minutes indicates fast-acting pharmacokinetics
Due to short half-life (~19 minutes), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Phase 3 clinical trial data available
- Multiple peer-reviewed studies available
- Oral administration available
Frequently Asked Questions
References (14)
- [11]
- [12]
- [1]Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J Intracavernosal self-injection with vasoactive intestinal polypeptide and phentolamine mesylate J Urol (1992)
- [2]Dinsmore WW, Hodges M, Hargreaves C, et al Intracavernosal injection of VIP and phentolamine mesylate for ED BJU Int (1999)
- [6]
- [3]Bennett AH, Carpenter AJ, Barada JH An improved vasoactive drug combination for a pharmacological erection program J Urol (1991)
- [4]Goldstein I, Carson C, Rosen R, et al Vasomax for the treatment of male erectile dysfunction World J Urol (2001)
- [5]Brindley GS Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence Br J Psychiatry (1983)
- [7]McMahon CG, Samali R, Johnson H Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy J Urol (1999)
- [8]Yafi FA, Jenkins L, Albersen M, et al Erectile dysfunction Nat Rev Dis Primers (2022)
- [11]Al-Mitwalli A, Holden F, Di Giovanni A, Sangster P, Ralph D, Lee WG, et al. Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction J Sex Med (2025)
→ Invicorp (aviptadil 25 mcg + phentolamine mesylate 2 mg) self-injected intracavernosally restored penetrative sexual activity in 59% of 308 men with alprostadil-refractory ED.
- [12]Sandhu D, Curless E, Dean J, Hackett G, Liu S, Savage D, Oakes R, Frentz G A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction International Journal of Impotence Research (1999)
→ In 304 men with non-psychogenic ED, intracavernosal VIP 25 mcg plus phentolamine mesylate (1 or 2 mg) in an auto-injector produced erections suitable for intercourse in ~84% during dose assessment and 75.1% vs 12% placebo (p<0.001) in the controlled phase; principal adverse event was transient facial flushing.
- [13]Dinsmore WW, Wyllie MG Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction BJU International (2008)
→ Review of Invicorp (VIP 25 mcg + phentolamine 1-2 mg): the two agents act complementarily (VIP on the veno-occlusive mechanism, phentolamine on arterial inflow), yielding efficacy in >=80% of men including prior treatment failures, with a notably low incidence of penile pain versus alprostadil.
- [14]Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction Journal of Urology (1992)
→ Early self-administration pilot of combined VIP and phentolamine mesylate produced erections adequate for intercourse in most men with psychogenic and arteriogenic impotence, establishing proof of concept for the vasoactive-peptide/alpha-blocker combination.
Aloe Vera
Aloe vera is a succulent plant containing over 200 bioactive compounds including polysaccharides, anthraquinones, vitamins, and enzymes with demonstrated anti-i
Alpha-Defensins (HNP-1 to HNP-4, HD-5, HD-6)
**Alpha-defensins** are a family of small (29-35 amino acid), cysteine-rich cationic antimicrobial peptides that constitute a major component of human innate im